Hostname: page-component-6766d58669-fx4k7 Total loading time: 0 Render date: 2026-05-17T21:16:37.398Z Has data issue: false hasContentIssue false
  • English
  • Français

Perioperative Intranasal Mupirocin for the Prevention of Surgical-Site Infections: Systematic Review of the Literature and Meta-Analysis

Published online by Cambridge University Press:  21 June 2016

Alexander J. Kallen ,
Chad T. Wilson  and
Robin J. Larson
Alexander J. Kallen*
Affiliation:
VA Outcomes Group, VA Medical Center, White River Junction, Vermont Dartmouth Medical School, Hanover, New Hampshire
Chad T. Wilson
Affiliation:
VA Outcomes Group, VA Medical Center, White River Junction, Vermont Dartmouth Medical School, Hanover, New Hampshire
Robin J. Larson
Affiliation:
VA Outcomes Group, VA Medical Center, White River Junction, Vermont Dartmouth Medical School, Hanover, New Hampshire
*
VA Outcomes Group, 215 North Main Street, VA Medical Center, White River Junction, VT 05009, Alexander.J.Kallen@dartmouth.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To review the evidence evaluating perioperative intranasal mupirocin for the prevention of surgical-site infections according to type of surgical procedure.

Design:

Systematic review and meta-analysis of published clinical trials.

Setting:

Studies included were either randomized clinical trial or prospective trials at a single institution that measured outcomes both before and after an institution-wide intervention (before-after trial). In all studies, intervention and control groups differed only by the use of perioperative intranasal mupirocin in the intervention group.

Patients:

Patients undergoing general or nongeneral surgery (eg, cardiothoracic surgery, orthopedic surgery, and neurosurgery).

Main Outcome Measure:

Risk of surgical-site infection following perioperative intranasal mupirocin versus usual care.

Results:

Three randomized and four before-after trials met the inclusion criteria. No reduction in surgical-site infection rate was seen in randomized general surgery trials (summary estimates: 8.4% in the mupirocin group and 8.1% in the control group; relative risk [RR], 1.04; 95% confidence interval [CI95], 0.81 to 1.33). In nongeneral surgery, the use of mupirocin was associated with a reduction in surgical-site infection in randomized trials (summary estimates: 6.0% in the mupirocin group and 7.6% in the control group; RR, 0.80; CI95, 0.58 to 1.10) and in before-after trials (summary estimates: 1.7% in the mupirocin group and 4.1% in the control group; RR, 0.40; CI95, 0.29 to 0.56).

Conclusions:

Perioperative intranasal mupirocin appears to decrease the incidence of surgical-site infection when used as prophylaxis in nongeneral surgery. Given its low risk and low cost, use of perioperative intranasal mupirocin should be considered in these settings.

Information

Type
Orginal Article
Information
Infection Control & Hospital Epidemiology , Volume 26 , Issue 12 , December 2005 , pp. 916 - 922
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Mangram, AJ, Horan, TC, Pearson, ML, Silver, LC, Jarvis, WR. Guideline for prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol 1999;20:250–278.CrossRefGoogle ScholarPubMed
2.Nichols, R. Preventing surgical site infections: a surgeon's perspective. Emerg Infect Dis 2001;7:220–224.Google Scholar
3.Martone, W, Nichols, R. Recognition, prevention, surveillance and management of surgical site infections: introduction to the problem and symposium overview. Clin Infect Dis 2001;33:S67–S68.CrossRefGoogle Scholar
4.Kirkland, KB, Briggs, JP, Trivette, SL, Wilkinson, WE, Sexton, DJ. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol 1999;20:725–730.CrossRefGoogle ScholarPubMed
5.Wenzel, RP, Perl, TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 1995;31:13–24.CrossRefGoogle ScholarPubMed
6.Emori, TG, Gaynes, RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;20:247–278.Google Scholar
7.Casewell, MW. The nose: an underestimated source of Staphylococcus aureus causing wound infection. J Hosp Infect 1998;40(suppl B):S3–S11.CrossRefGoogle ScholarPubMed
8.Doebbeling, BN, Breneman, DL, Neu, HC, et al.Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. Clin Infect Dis 1993;17:466–474.CrossRefGoogle ScholarPubMed
9.Perl, TM. Prevention of Staphylococcus aureus infections among surgical patients: beyond traditional perioperative prophylaxis. Surgery 2003;134:S10–S17.CrossRefGoogle ScholarPubMed
10.Fernandez, C, Gaspar, C, Torrellas, A, et al.A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. J Antimicrob Chemother 1995;35:399–408.CrossRefGoogle ScholarPubMed
11.Horan, TC, Gaynes, RP, Martone, W, Jarvis, WR, Emori, TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 1992;13:606–608.Google Scholar
12.Cimochowski, GE, Harostock, MD, Brown, R, Bernardi, M, Alonzo, N, Coyle, K, Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. Ann Thorac Surg 2001;71:1572–1578.Google Scholar
13.Perl, TM, Cullen, JJ, Wenzel, RP, et al.Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002;346:1871–1877.CrossRefGoogle ScholarPubMed
14.Harris, RP, Helfand, M, Woolf, SH, et al.Current methods of the U.S. Preventive Services Task Force: a review of the process. Am J Prev Med 2001;20:21–35.Google Scholar
15.Kalmeijer, MD, Coertjens, H, van Nieuwland-Bollen, PM, et al.Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. Clin Infect Dis 2002;35:353–358.CrossRefGoogle Scholar
16.Suzuki, Y, Kamigaki, T, Fujino, Y, Tominaga, M, Ku, Y, Kuroda, Y. Randomized clinical trial of preoperative intranasal mupirocin to reduce surgical-site infection after digestive surgery. Br J Surg 2003;90:1072–1075.Google Scholar
17.Kluytmans, JA, Mouton, JW, VandenBergh, MF, et al.Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 1996;17:780–785.CrossRefGoogle ScholarPubMed
18.Yano, M, Doki, Y, Inoue, M, Tsujinaka, T, Shiozaki, H, Monden, M. Preoperative intranasal mupirocin ointment significantly reduces postoperative infection with Staphylococcus aureus in patients undergoing upper gastrointestinal surgery. Surg Today 2000;30:16–21.Google Scholar
19.Gernaat-van der Sluis, AJ, Hoogenboom-Verdegaal, AM, Edixhoven, PJ, Spies-van Rooijen, NH. Prophylactic mupirocin could reduce orthopedic wound infections: 1,044 patients treated with mupirocin compared with 1,260 historical controls. Acta Orthop Scand 1998;69:412–414.CrossRefGoogle Scholar
20.Laupland, KB, Conly, JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence based review. Clin Infect Dis 2003;37:933–938.Google Scholar
21.VandenBergh, MF, Kluytmans, JA, van Hout, BA, et al.Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery. Infect Control Hosp Epidemiol 1996;17:786–792.CrossRefGoogle ScholarPubMed